Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Fenglong Xie¹, Lang Chen¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…
Abstract Number: 495 • 2018 ACR/ARHP Annual Meeting
Characteristics of Metabolic Syndrome in Men and Women with Early Rheumatoid Arthritis
Bindee Kuriya¹, Orit Schieir², Marie-France Valois³, Janet E. Pope⁴, Gilles Boire⁵, Louis Bessette⁶, Carter Thorne⁷, Diane Tin⁸, Carol A Hitchon⁹, Glen Hazlewood¹⁰, Susan J. Bartlett¹¹, Edward C. Keystone¹², Vivian P. Bykerk¹³ and Lillian Barra¹⁴, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²McGill University, Montreal, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴Department of Medicine, University of Western Ontario, London, ON, Canada, ⁵Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁷University of Toronto, Newmarket, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, ¹¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Mount Sinai Hospital, Toronto, ON, Canada, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Medicine, Microbiology and Immunology, The University of Western Ontario, London, ON, Canada
Prevalence and Characteristics of Metabolic Syndrome in Men and Women With Early Rheumatoid ArthritisB. Kuriya, O. Schieir, M.F. Valois, J.E. Pope, G. Boire, L. Bessette,…
Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Sytske Anne Bergstra¹, Lai-Ling Winchow², Elizabeth Murphy³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, João E. Fonseca⁶, Cornelia F. Allaart¹ and Robert B.M. Landewé⁷, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²University of the Witwatersrand, Johannesburg, South Africa, ³University Hospital Wishaw, Scotland, Wishaw, United Kingdom, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…
Abstract Number: 547 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials
Elisabeth G. Brilman¹, Joy A. van der Pol¹, Pascal HP de Jong^2,3, Angelique EAM Weel^2,3, JMW Hazes², Tom W.J. Huizinga⁴ and Cornelia F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: What is the optimal glucocorticoid (GC) bridging therapy with MTX monotherapy in early arthritis? Methods: In trial A, early RA and UA (arthritis in ≥1…
Abstract Number: 565 • 2018 ACR/ARHP Annual Meeting
Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
Thierry Dervieux¹, Marie Grosjean², Chuang Jiang^3,4, Kelley Brady¹, Kjeld Schmiegelow², Joel Kremer⁵ and Jun Yang⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²University Hospital Rigshospitalet, Copenhagen, Denmark, ³Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China, ⁴Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate (MTX) is anti-folate activated to MTX polyglutamates (MTXPGs). MTX metabolism includes multiple enzyme-mediated reactions and genetic polymorphisms in these genes are linked to…
Abstract Number: 466 • 2017 ACR/ARHP Annual Meeting
Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Martin Pelletier¹, Paul R. Fortin^1,2, Marie-Pier Longchamps¹, Geneviève Parent¹, Hadrien Benk-Fortin¹, Anne-Sophie Julien³, Nathalie Amiable¹, Emmanuelle Rollet-Labelle¹, Laetitia Michou², Louis Bessette² and Philippe A. Tessier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ³Clinical Research Platform, CHU de Québec-Université Laval Research Center, Québec, QC, Canada
Background/Purpose: Methotrexate (MTX) is the first line treatment for patients with rheumatoid arthritis (RA). For over 30% of patients, MTX fails to diminish DAS28 score…
Abstract Number: 517 • 2017 ACR/ARHP Annual Meeting
Evaluation of the Effectiveness of Injectable Methotrexate for the Treatment of Rheumatoid Arthritis
Jenny Wan¹, Michele Spence², Fang Niu², Rita Hui³, Stephen Cheng¹, Logan Saito⁴ and Antony Lin⁵, ¹Kaiser Permanente Drug Information Services - California Regions, Downey, CA, ²Kaiser Permanente Pharmacy Outcomes Research Group, Downey, CA, ³Kaiser Permanente Pharmacy Outcomes Research Group, Oakland, CA, ⁴Kaiser Permanente Southern California Clinical Pharmacy Services, Downey, CA, ⁵Rheumatology, Kaiser Permanente Fontana Medical Center, Fontana, CA
Background/Purpose: Systemic methotrexate (MTX) is the first-line disease-modifying antirheumatic drug (DMARD) for treating early and established rheumatoid arthritis (RA). When compared to oral MTX, subcutaneous…
Abstract Number: 518 • 2017 ACR/ARHP Annual Meeting
The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients
Antony Lin¹, Qiaowu Li², Jiaxiao Shi², Serena Lin³, Danielle Wang⁴, Jenny Wan⁵, Kevin Lee³, Hung-Fu Tseng² and TC Cheetham⁶, ¹Southern California Permanente Medical Group, Pasadena, CA, ²Department of Research and Evaluation, Kaiser Permanente, Pasadena, CA, ³Stanford University, Stanford, CA, ⁴UCI Medical Center, Irvine, CA, ⁵Kaiser Permanente Drug Information Services - California Regions, Downey, CA, ⁶Western University of Health Sciences, Pomona, CA
Background/Purpose: To investigate the efficacy and safety of zoster vaccines administered in rheumatoid arthritis(RA) patients taking methotrexate(MTX). Methods: By reviewing data through the…
Abstract Number: 534 • 2017 ACR/ARHP Annual Meeting
Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study
René Westhovens¹, Annegret Van der Aa², Corinne Jamoul², Chantal Tasset² and Pille Harrison², ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
Abstract Number: 539 • 2017 ACR/ARHP Annual Meeting
Comparison of Oral Versus Parenteral Methotrexate in Rheumatoid Arthritis: A Meta-Analysis
Sahar Janjua¹, Andreea Bujor¹, Michael P. LaValley², Josefina Duran³, Jürgen Braun⁴ and David T. Felson⁵, ¹Department of Rheumatology, Boston Medical Center, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Pontificia Universidad Católica de Chile, Santiago, Chile, ⁴Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Methotrexate (MTX) is the mainstay first-line therapy for rheumatoid arthritis (RA), and it can be given orally or parenterally. Bioavailability of oral MTX may…
Abstract Number: 1438 • 2017 ACR/ARHP Annual Meeting
Is It Necessary to Weight By Weight the Dosage of MTX in RA Patients? Results from Obsevational Analysis of Baseline Data of a Phase III Trial
Alain Saraux¹, Christophe Hudry², Elena Zinovieva³ and Hélène Herman-Demars³, ¹Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ²AP-HP Hôpital Cochin, Paris, France, ³Medical Department Nordic Pharma, Paris, France
Background/Purpose: In inflammatory rheumatic diseases, pharmacokinetics of MTX may be modified by patients’ weight [1]. The rheumatologists are though reluctant to prescribe a high dosage…
Abstract Number: 1738 • 2017 ACR/ARHP Annual Meeting
The Pattern of Proinflamatory Cytokine Expression By CD4+ T Lymphocytes Segregates the Clinical Response to Methotrexate in Recently Diagnosed Rheumatoid Arthritis Patients
Jorge Monserrat Sanz¹, Ana Maria Gómez Lahoz², Cristina Bohórquez Heras³, Maria Dolores Sosa Reina², Atusa Movasat³, Ana Pérez Gómez³, Lucía Ruiz Gutiérrez³, Ana Sánchez Atrio³, Eduardo Cuende Quintana³, Maria José León³, David Diaz², Fernando Albarrán Hernández³ and Melchor Alvarez-Mon^2,3, ¹Laboratory of Inmune System Diseases, Deparment of Medicine and Medical Specialties. IRYCIS. University of Alcalá. Madrid. Spain, Alcalá de Henares. Madrid, Spain, ²Laboratory of Inmune System Diseases, Deparment of Medicine and Medical Specialties. IRYCIS. University of Alcalá. Madrid. Spain, Alcalá de Henares, Madrid, Spain, ³University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain
Background/Purpose: Mechanisms regulating the autoimmune response in rheumatoid arthritis (RA) are not well understood. However, it is known that T CD4+ lymphocytes play a pivotal…
Abstract Number: 2380 • 2017 ACR/ARHP Annual Meeting
The Use of Fibroscan in Detecting Early Liver Fibrosis in RA Patients on Long Term MTX with Normal Liver Enzymes
Malack Alachkar¹, T Mathialahan², Sandra Walsh² and Vun Lim³, ¹Rheumatology, The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ²Gastroenterology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom, ³Rheumatology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom
Background/Purpose: FibroScan (FS) is a non-invasive investigation that allows assessment of possible liver fibrosis by measuring liver stiffness. There are studies which confirm that MTX-related…
Abstract Number: 2479 • 2017 ACR/ARHP Annual Meeting
Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese¹, Erin K. Mangan², Toshio Kimura², Melitza Iglesias-Rodriguez³ and Tom W.J. Huizinga⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Cambridge, MA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3, 52-week MOBILITY study (NCT01061736), sarilumab (150 or 200 mg subcutaneously every 2…
Abstract Number: 2480 • 2017 ACR/ARHP Annual Meeting
Improvements in Remission and Low Disease Activity Are Achieved with Ongoing Sarilumab Treatment, in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies
Mark C. Genovese¹, Erin K. Mangan², Jonathan Fay², Toshio Kimura², Hubert van Hoogstraten³ and Roy Fleischmann⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rɑ. Efficacy and safety of sarilumab (150 or 200 mg subcutaneously every 2 wks [q2w]) + conventional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].